Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.
Journal Title: Pharmacological Reports - Year 2010, Vol 62, Issue 1
Abstract
The aim of this study was to compare the action of fenofibrate on monocyte cytokine release between patients with isolated mixed dyslipidemia and dyslipidemia coexisting with prediabetic states in relationship with its metabolic actions.We compared 96 primary mixed dyslipidemic patients and 29 age-, sex- and weight-matched control subjects with normal lipid profile. Depending on glucose metabolism, dyslipidemic patients were allocated into one of three treatment groups: isolated dyslipidemia, dyslipidemia coexisting with impaired fasting glucose (IFG) and dyslipidemia coexisting with impaired glucose tolerance (IGT). Lipid profile, fasting and 2-h post-glucose load plasma glucose levels, HOMA and monocyte release of interleukin-1beta and MCP-1 were assessed at baseline and after 30 and 90 days of micronized fenofibrate treatment (267 mg/daily). Compared to monocytes from control subjects, monocytes of dyslipidemic patients released a greater amounts of interleukin-1beta and MCP-1. MCP-1 release was higher in the IFG group than in the remaining groups of dyslipidemic patients. In all groups of dyslipidemic patients, micronized fenofibrate reduced monocyte release of interleukin-1beta and MCP-1, and this effect was stronger in prediabetic subjects. Fenofibrate treatment also decreased HOMA in IFG and IGT patients, fasting plasma glucose in IFG subjects and 2-h post-glucose load plasma glucose in IGT patients. The observed differences between the studied groups regarding fenofibrate action on glucose homeostasis and cytokine release suggest that fibrate therapy may bring particular benefits to persons with metabolic syndrome.
Authors and Affiliations
Robert Krysiak, Aldona Stachura-Kułach, Bogusław Okopień
Keywords
Related Articles
- EP ID EP149952
- DOI -
- Views 82
- Downloads 0
Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1.
Background: Expression of drug-metabolizing enzymes and drug transporters in liver is mainly regulated by a system of nuclear receptors. The aim of the current study was to investigate the expression of nuclear receptors...
Effects of baclofen and L-AP4 in passive avoidance test in rats after hypoxia-induced amnesia.
Hypoxia-induced cognitive deficits are mainly due to disturbances of the balance between the GABAergic and glutamatergic systems. Acquisition, consolidation and retention impairment in passive avoidance test, hypolocomot...
Influence of cimetidine on the anticonvulsant activity of conventional antiepileptic drugs against pentetrazole-induced seizures in mice.
The aim of this study was to evaluate the effects of acute (1 day) andchronic (7 days) administrations of cimetidine, an H(2) histamine receptor antagonist, on the protective activity of conventional antiepileptic drugs...
Antiulcerative effect of dexmedetomidine on indomethacin-induced gastric ulcer in rats.
A gastroprotective effect occurs when α(2) receptors are innervated. The dextro isomer of medetomidine, dexmedetomidine, is a highly selective α(2)-adrenoreceptor agonist. The aim of this study was to investigate whether...
Synthesis and pharmacological properties of a new fluorescent opioid peptide analog.
Biphalin, is a palindromic peptide [(Tyr-D-Ala-Gly-Phe-NH-)(2)] in which two opioid pharmacophores are connected "tail-to-tail." This peptide displays a broad affinity for all opioid receptors (mu, delta and kappa) as we...